Estimates show that globally 27 million people will have NASH—an asymptomatic, progressive and burgeoning liver disease that can lead to increased liver-related mortality and morbidity—by 2030.
FibroScan®, an FDA cleared technology for the diagnosis and monitoring of adult patients as part of an overall evaluation of liver health, directly and non-invasively measures physical properties of stiffness and liver fat.
As sponsors, we want to both celebrate the progress we have already achieved with wider use of FibroScan® and galvanize the fight to help reverse the progression of liver disease. The need for early identification, assessment and monitoring of liver fat and stiffness has never been more critical.
Spread the word around you by sharing information, social media posts and visuals available in the dedicated toolkit!
|Toolkit for download here (.pdf)||JPG Graphics kit for download here (.zip)|